$The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial$

The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial

Aims To determine the cost‐effectiveness of dapagliflozin, added to usual care, in patients with heart failure (HF) with mildly reduced or preserved ejection fraction for the UK, German and Spanish payers using detailed patient‐level data from the Dapagliflozin Evaluation to Improve the LIVEs of Pat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of heart failure 2023-08, Vol.25 (8), p.1386-1395
Hauptverfasser:	Booth, David, Davis, Jason A., McEwan, Phil, Solomon, Scott D., McMurray, John J.V., De Boer, Rudolf A., Comin‐Colet, Josep, Bachus, Erasmus, Chen, Jieling
Format:	Artikel
Sprache:	eng
Schlagworte:	Cost‐effectiveness Dapagliflozin Heart failure Mildly reduced ejection fraction Preserved ejection fraction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!